Mutations in PKD1 and PKD2 cause autosomal dominant polycystic kidney disease (ADPKD), the most common renal genetic disease, leading to the dysregulation of renal tubules and the development of cystic growth that compromises kidney function. Despite significant advances in recent decades, there remains a considerable unmet clinical need, as current therapeutics are not effective at slowing or halting disease progression. Although preclinical animal models have been used extensively, the translatability of such findings is uncertain and human-relevant disease models are urgently needed. The advent of pluripotent stem cells (PSCs) and their ability to more accurately recapitulate organ architecture and function has allowed for the study of renal disease in a more physiological and human-relevant setting. To date, many research groups have studied ADPKD using PSC-derived kidney organoids, identifying many dysregulated pathways and screening drug candidates that may yield effective therapies in the clinic. In this review article, we discuss in detail the development of PSC-derived kidney organoids as ADPKD models and how they have advanced our understanding of the disease’s pathogenesis, as well as their limitations and potential strategies to address them.
Building similarity graph...
Analyzing shared references across papers
Loading...
Alexandru Scarlat
Susanna Tomasoni
Piera Trionfini
Biomedicines
Mario Negri Institute for Pharmacological Research
Building similarity graph...
Analyzing shared references across papers
Loading...
Scarlat et al. (Fri,) studied this question.
www.synapsesocial.com/papers/689a0945e6551bb0af8cee69 — DOI: https://doi.org/10.3390/biomedicines13071766